clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Published 1 year ago • 126 plays • Length 2:45Download video MP4
Download video MP3
Similar videos
-
2:26
serum biomarkers as predictors of disease progression in smoldering myeloma
-
5:11
istopmm: the psychological effects of mgus screening and changes to clinical presentation of myeloma
-
0:42
challenges with designing clinical trials for smoldering myeloma
-
3:00
genomic features of myeloma precursor conditions can predict clinical progression
-
0:49
genomic differences between smoldering and multiple myeloma
-
3:48
the current treatment landscape in multiple myeloma
-
5:27
when patients test as having borderline high-risk smoldering myeloma, should they receive treatment?
-
4:12
when should smoldering multiple myeloma patients start treatment?
-
3:37
genomic patterns in smoldering myeloma enhance timing of treatment initiation
-
3:37
smoldering myeloma: state of the art
-
0:56
how do we define smoldering multiple myeloma?
-
4:41
genomic characterization of non-progressor smoldering multiple myeloma
-
5:20
approaching smoldering myeloma
-
2:25
pre-clinical activity of ucartcs1 in multiple myeloma
-
5:06
treatment strategies for smoldering myeloma
-
1:59
smoldering multiple myeloma: what is the current definition & new screening programme
-
1:38
the genomic definition of high-risk myeloma
-
2:37
meta-analysis of studies on biomarker-defined early multiple myeloma
-
4:29
smoldering myeloma: monitoring patients and deciding when to treat
-
4:26
outcomes of ird in r/r multiple myeloma in routine clinical practice
-
2:54
what is the future for myeloma clinical trials?